Please cite as: CSH Protocols; 2007; doi:10.1101/pdb.prot4636

This Protocol
Right arrow Full Text
Right arrow Update/discuss this protocolDiscussion icon
Right arrow Alert me when this protocol is cited
Right arrow Alert me when comments are published
Right arrow Alert me if a correction is posted
Services
Right arrow Similar protocols in this database
Right arrow Alert me to new releases of protocols
Right arrow Save to Personal Folders
Right arrow Download to citation manager
Right arrow Printer-friendly versionPrinter-friendly version
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eblen, S. T.
Right arrow Articles by Weber, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Eblen, S. T.
Right arrow Articles by Weber, M. J.
Related Collections
Right arrow Proteins and Proteomics, general
Right arrow Phosphorylation Site Mapping
Right arrow Proteomics
Right arrow Protein: Protein Interactions, general
Right arrow Design of Novel Interactions
Right arrow See and buy materials for this protocol
Right arrowRelated Protocols
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Legend icon

protocolProtocol

Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Identification of a Mutant Kinase/ATP Analog Pair

Scott T. Eblen, N. Vinay Kumar, and Michael J. Weber

This protocol was adapted from "Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates," Chapter 24, in Protein-Protein Interactions (eds. Golemis and Adams). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2005.


INTRODUCTION

This protocol describes a method for studying protein kinases and their substrates by generation of mutant kinase enzymes that can incorporate ATP analogs into the substrate. This method was used to identify substrates of extracellular signal-regulated kinase 2 (ERK2). Once mutations (called "pocket mutations") have been generated in the kinase, the next step is to screen ATP analogs for their compatibility with the kinase mutant. This screening is best performed in a two-step process. The first step involves assaying the ability of an ATP analog to inhibit the incorporation of radioactive phosphate from normal [{gamma}-32P]ATP into a known substrate in an in vitro kinase reaction. Because certain analogs might be able to interact with the ATP-binding site of the kinase but be unable to be used by the kinase as an ATP source, it is also necessary to directly test the ability of the mutant kinase to phosphorylate a substrate with analog ATP. Doing this requires either radiolabeled ATP analogs or, preferably, a phospho-specific antibody to the phosphorylation site on the known substrate. (A phospho-specific antibody allows a large number of ATP analogs to be screened without the need for radioactivity.) The kinase/ATP analog pair that provides the best phosphorylation of the substrate is then used for future experiments. Only those analogs that cannot be used by the wild-type kinase and other cellular kinases are chosen.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Protocols

Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Phosphorylation of Kinase-Associated Substrates
Scott T. Eblen, N. Vinay Kumar, and Michael J. Weber
CSH Protocols 2007: 4638. [Abstract] [Full Text]

Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Phosphorylation of Substrates in Cell Lysates with Exogenous Kinase
Scott T. Eblen, N. Vinay Kumar, and Michael J. Weber
CSH Protocols 2007: 4639. [Abstract] [Full Text]



See and buy materials for this protocol:

SIGMA-ALDRICH Products for this Protocol